If you require further searching capabilities for announcements please email: data@nzx.com
Notice of Annual Shareholders' Meeting DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge Limited (NZX, ASX: PEB) today gives notice its Annual Shareholders’ Meeting will be held at MUFG Corporate Markets Board Room, Level 30, PwC Tower, 15 Customs Street West, in Auckland and online on Wednesday 6 August 2025, commencing at 3.00pm. Attached is the Notice of Meeting, which includes details for proxy voting, the online meeting details, the resolutions for shareholder consideration and an Appraisal Report relating to two of the resolutions. Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer. For more information: Investors: Dr Peter Meintjes Chief Executive Pacific Edge P: 022 032 1263 Media: Richard Inder The Project P: +64 21 645 643 Overview Pacific Edge: www.pacificedgedx.com Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. Cxbladder: www.cxbladder.com Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency. Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence. Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.